longevitydocs.™ ROOMS™ are live, unscripted audio conversations held directly inside longevitydocs.ai, where verified longevity physicians drop in to host, question, and debate one another in real time, no recordings, no slide decks, just the conversation. The platform also includes Chat, where private clinical conversations happen inside the vetted physician community, a News Hub that tracks longevity industry news daily, and Hippo, the platform's AI, trained specifically on the longevitydocs.™ curriculum and archived ROOMS™ sessions. ROOMS™ are the live piece: twenty-minute peer-led sessions where longevity physicians host and join focused discussions, asking questions, sparking debate, and sharing clinical insights in real time.

Access is limited to verified, licensed MDs and DOs who are members of longevitydocs.™ You can apply for membership here, and see the full membership benefits breakdown here if you want the details before you apply. ROOMS™ are never recorded; they happen live so physicians can speak candidly to other clinicians. These conversations move faster than journals.

Here's what three of our physicians shared this month. If you missed it, last month's recap covered five more longevity physicians across AI agents, HRT after breast cancer, peptide protocols, perimenopausal weight loss, and cognitive longevity.

Dr. Suneer Chander

Navigating Risks in Telemedicine: The Real Threat Is Regulatory, Not Malpractice

ER physician and Air Physician Academy co-founder Dr. Suneer Chander argued that malpractice fear is overblown in telemedicine, the real exposure is regulatory. He outlined a four-bucket compliance framework (licensure, modality, standard of care, treatment-specific rules) and warned that state-by-state nuance, plus evolving peptide and compounding-pharmacy rules, requires physicians to build active tracking systems.

Key Takeaways

• Malpractice risk in telemedicine is low; insurance underwriters price it accordingly (~$5,000-$12,000/yr nationally vs ~$30,000 for EM, $40,000-$200,000 for OB-GYN), because telemedicine is mostly low-acuity care with no procedures.

• When malpractice claims do arise they are rare but serious; roughly two-thirds involve misdiagnosis, so the key discipline is knowing when telemedicine is inappropriate and referring to in-person care.

• The real risk lies in regulatory compliance, framed in four buckets: (1) licensure, (2) modality, (3) standard of care, (4) treatment-specific rules.

• Physicians must be licensed in the state where the patient is physically located; Sunir holds licenses in all 50 states + DC to see patients nationally.

• Modality rules vary by state; synchronous video, audio-only, and asynchronous store-and-forward/questionnaire care are permitted differently (e.g., Texas may restrict asynchronous chat that Mississippi allows).

• Treatment-specific rules (controlled substances, GLP-1s, TRT, peptides) vary state-by-state and are set both federally and at the state level; the FDA/PCAT peptide fight is only part of the picture.

• A single mistake in one state gets reported to all state medical boards where you're licensed, forcing you to defend yourself everywhere, even over rules that don't exist in some of those states.

• Regulations shift roughly every 3-6 months; physicians should build frameworks to track telemedicine, peptide, and compounding-pharmacy rule changes as they evolve.

Clinical Pearls

• New-state expansion checklist: verify licensing/CME/PDMP requirements, confirm permitted modality, confirm you can meet brick-and-mortar standard of care via telemedicine, and check therapeutic-specific restrictions.

• For peptides specifically, also ask: what are the federal rules, the state-by-state rules, and which compounding pharmacy (503A vs 503B) is being used and whether it's compliant state-by-state.

• Track licensure/renewal dates via a system, as simple as a spreadsheet or a service like Mockingbird.

• Patients with multiple residences: technically you should be licensed where they're physically located; established relationships in another state are low medical-board priority, but handle per your risk tolerance.

• International telemedicine is illegal if reimbursed by Medicare/Medicaid/TRICARE; cash-pay is possible if self-employed with policies, cybersecurity, and PHI protections, the main concern is data-breach risk, not legal risk.

Mentioned FDA · PCAT committee · GLP-1s · TRT · peptide therapy · compounding pharmacies (503A / 503B) · PDMP · CME · Mockingbird · Medicare · Medicaid · TRICARE · Air Physician Academy

Dr. Amy Killen

Estrogen, Statins, and Lipids: The Untested Intersection in Women's Longevity Medicine

Dr. Amy Killen discussed how estrogen loss at menopause and statin therapy exert overlapping negative effects, particularly on mitochondria and insulin sensitivity, in women, yet the interaction between hormone therapy and statins has not been studied since the 1990s. She argued for prioritizing hormone therapy and lifestyle before statins in appropriate patients and challenged long-held assumptions about lower-dose estrogen being safer.

Key Takeaways

• A June 2026 observational BLUEMET-type study of about 1,200 postmenopausal women across 9 countries found statin users reported more severe menopause symptoms (47% vs 31%), more severe muscle and joint pain (53% vs 34%), and roughly twice the rate of sarcopenia.

• No study since the late 1990s has examined how menopausal status or estrogen therapy affects statin efficacy or side effects; JUPITER is the only major lipid trial that even addresses menopause status, and it does so by excluding premenopausal women.

• Estrogen acts protectively at multiple levels of lipid metabolism (production, absorption, removal); its loss at menopause drives up LDL, ApoB, and triglycerides.

• Statins and estrogen loss produce a "double hit" on mitochondria (statins block CoQ10 synthesis; estrogen loss reduces mitochondrial resilience) and both worsen insulin resistance, likely explaining why statins cause more muscle side effects and diabetes risk in women.

• 1990s studies (using Premarin) found statin plus estrogen combinations were synergistic, and statins reduced Premarin-associated CRP elevation and early cardiovascular risk, but no one tested whether estrogen makes statins safer or more effective.

• Statin primary-prevention benefit in women is weak; Killen suspects adding hormone therapy could improve outcomes but acknowledges no trial exists.

• Low cholesterol from statins does not appear to significantly reduce estradiol or testosterone (much is produced locally), though the MESA study showed lower DHEA in statin users, a proportionally larger drop in postmenopausal women.

• Killen questions the "lowest dose, shortest duration" estrogen dogma, noting it was never actually studied; a 2019 Lancet analysis showed the lowest Premarin dose (0.3 mg) had the highest associated breast cancer risk, with all other doses carrying equal risk.

Clinical Pearls

• Prefer starting hormone therapy plus lifestyle before statins in lower-risk perimenopausal/menopausal women; do both simultaneously only if high cardiovascular risk.

• When a statin is needed, low-dose statin (e.g., 10 mg) plus low-dose ezetimibe (10 mg) reduces side effects versus high-dose statin monotherapy.

• Use a Boston Heart sterol test to identify hyper-producers vs hyper-absorbers and guide statin vs ezetimibe selection.

• Consider CoQ10 supplementation (data mixed) and DHA, which emerging mouse data suggests may help statin-related musculoskeletal and blood-sugar side effects in females.

• Be cautious with statins in patients prone to diabetes/prediabetes or with existing mitochondrial dysfunction; consider alternatives like bempedoic acid or PCSK9 inhibitors (Repatha).

• Oral estradiol/Premarin lowers LDL, ApoB, and even Lp(a) more effectively than transdermal; transdermal is safer (no clot risk) and better for triglycerides, but oral estrogen can raise triglycerides.

Mentioned BLUEMET study (Menopause, June 2026) · JUPITER trial · MESA study · 2019 Lancet estrogen/breast cancer study · Boston Heart sterol test · Premarin · estradiol · progesterone · testosterone · ezetimibe · bempedoic acid · Repatha (PCSK9 inhibitor) · CoQ10 · DHA/EPA · CRP · Lp(a) · ApoB · DHEA

Dr. Dobri Kiprov

Therapeutic Plasma Exchange: From Autoimmune Subtractive Medicine to Longevity Applications

Dr. Dobri Kiprov, a 40-year veteran of therapeutic apheresis, explained how therapeutic plasma exchange (TPE) removes pro-inflammatory factors and may reverse aspects of immune aging. He reviewed clinical experience in autoimmune disease (myasthenia gravis, lupus), the AMBAR Alzheimer's trial, and a placebo-controlled longevity study, plus emerging adsorption-column filtration technology.

Key Takeaways

• TPE is performed via centrifugal or membrane apheresis to separate plasma from cells; more than 90 diseases are treated with it, the majority autoimmune, with recommendations categorized by the American Society for Apheresis every three years.

• The concept is "subtractive medicine": removing offending factors (autoantibodies, cytokines, chemokines, circulating immune complexes) rather than adding drugs that can trigger new pathways and side effects.

• Beyond removal, TPE is now understood to alter T and B cell subsets and cause both down- and up-regulation of proteins, relevant to longevity medicine and immune control.

• Kiprov targets three aging hallmarks: inflammation, immunosenescence, and cell senescence/SASP; TPE reportedly removes SASP factors effectively and can restore proliferation of naive CD4 and CD8 T cells, shown by flow cytometry.

• Aged patient plasma kills incubated stem cells, but after TPE the same patient's plasma supports rapid stem cell growth, suggesting TPE as an adjunct to prep the milieu for stem cell, peptide, or other regenerative interventions.

• The AMBAR Alzheimer's trial (sponsored by Grifols) tested amyloid removal via albumin binding; amyloid was found not to be the sole cause, but outpatient TPE proved safe and outcomes reportedly exceeded anti-amyloid monoclonals.

• A double-blind, placebo-controlled longevity study in patients age 50+ showed a reduction in biologic age (2-3 points/years) and an immune system 7-9 years biologically younger, plus SASP/inflammatory marker reduction, measured by DNA methylation clocks including organ-specific aging.

• Newer indications discussed include chronic fatigue syndrome, long COVID (both infection- and vaccine-related), Lyme disease, and dermatologic conditions like scleroderma and lupus.

Clinical Pearls

• TPE is done exclusively with albumin replacement (not plasma) in Kiprov's practice.

• IVIG is used to prevent antibody rebound/relapse: small doses after each procedure, with higher doses once the TPE course is completed; protocol individualized by symptoms rather than fixed dosing.

• Outpatient TPE is safe: under 5% mostly-mild side effects in the US; Barcelona saw 7-8% due to catheter/central vascular access, which Kiprov avoids for this indication.

• Establishing the source/diagnosis of inflammation is essential; TPE tones down inflammation but does not address the underlying driver.

• Adsorption-column filtration (Kiprov is medical director) is complementary, not a replacement: it precisely removes toxins, microplastics, and heavy metals while sparing beneficial molecules like clotting factors, but is poor at removing autoantibodies (IgG/IgM).

• Patient safety requires experienced personnel; beware TPE offered in "pop-up med spa" settings.

Mentioned American Society for Apheresis (ASFA) · AMBAR Alzheimer's study · Grifols · albumin · IVIG · DNA methylation clocks · flow cytometry · SASP (senescence-associated secretory phenotype) · adsorption/filtration column · International Society for Apheresis

Frequently Asked Questions